The phase 3 INO-VATE ALL study (NCT01564784) compared treatment with InO to standard-of-care chemotherapy in 326 adult patients with relapsed or refractory, CD22-positive B-ALL. Here, CD22 is linked to acute lymphoblastic leukemia.